Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
What is Integra Lifesciences Holdings OCF Margin %?
Integra Lifesciences HoldingsSTU:IL3 +2.50%74 OCF Margin % is 2.50% as of Mar. 2026, which is 80% below its 10-year median of 12.65. GuruFocus rates STU:IL3 with a GF Score™ of 74/100 and a GF Value™ of €20.79 (Modestly Undervalued). The stock has 11 warning signs investors should review. Among 817 Medical Devices & Instruments companies, Integra Lifesciences Holdings ranks worse than 53.61% on this metric.
The historical rank and industry rank for Integra Lifesciences Holdings's OCF Margin % or its related term are showing as below:
STU:IL3'
s OCF Margin % Range Over the Past 10 Years
Min: 3.08 Med: 12.65 Max: 20.26
Current: 4.33
During the past 13 years, the highest OCF Margin % of Integra Lifesciences Holdings was 20.26%. The lowest was 3.08%. And the median was 12.65%.
STU:IL3's OCF Margin % is ranked worse than 53.61% of 817
companies
in the Medical Devices & Instruments industry
Industry Median: 5.82
vs STU:IL3: 4.33
Integra Lifesciences Holdings OCF Margin % Related Terms
Integra Lifesciences Holdings OCF Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:IL3 vs ATEC, AHCO, INSP: OCF Margin % Comparison
For the Medical Devices subindustry, Integra Lifesciences Holdings's OCF Margin %, along with its competitors' market caps and OCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Integra Lifesciences Holdings OCF Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Integra Lifesciences Holdings's OCF Margin % distribution charts can be found below:
* The bar in red indicates where Integra Lifesciences Holdings's OCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Integra Lifesciences Holdings (STU:IL3) has a OCF Margin % of 2.50% as of Mar. 2026. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Integra Lifesciences Holdings and its competitors. This is 80% below median its historical median of 12.65. Over the past decade, Integra Lifesciences Holdings' OCF Margin % has ranged from 3.08 to 20.26. According to the industry distribution chart, Integra Lifesciences Holdings ranks #438 out of 817 companies in the Medical Devices & Instruments industry, placing it in the top 53.6%.
Is Integra Lifesciences Holdings' OCF Margin % too high?
Integra Lifesciences Holdings' current OCF Margin % of 2.50% is 80% below median its 10-year median of 12.65. Over the past 10 years, this metric has ranged from a low of 3.08 to a high of 20.26. The Medical Devices & Instruments industry median OCF Margin % is 5.82. Integra Lifesciences Holdings' value of 2.50% is 57% below this industry median. Based on the distribution chart, Integra Lifesciences Holdings ranks #438 out of 817 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Integra Lifesciences Holdings has a GF Score™ of 74/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Integra Lifesciences Holdings' OCF Margin % compare to ATEC and AHCO?
According to the Medical Devices & Instruments industry distribution chart, Integra Lifesciences Holdings ranks #438 out of 817 companies for OCF Margin %. This places Integra Lifesciences Holdings in the lower half of its industry. The industry median OCF Margin % is 5.82. Integra Lifesciences Holdings' value of 2.50% is 57% below this benchmark. Historically, Integra Lifesciences Holdings' own OCF Margin % has ranged from 3.08 to 20.26 over the past decade. While the company's 10-year median is 12.65 vs. the industry median of 5.82, Integra Lifesciences Holdings has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Margin % for a Medical Devices & Instruments company?
The median OCF Margin % among Medical Devices & Instruments companies is 5.82, based on 817 companies in the industry. Companies in the top quartile (top 25%) have a OCF Margin % significantly above this median, while those in the bottom quartile fall well below. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Integra Lifesciences Holdings's current OCF Margin % of 2.50% is 57% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Margin % mean?
A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Integra Lifesciences Holdings and its competitors. For the Medical Devices & Instruments industry, the median OCF Margin % is 5.82 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Integra Lifesciences Holdings's current OCF Margin % is 2.50%, which is 80% below median its own 10-year median of 12.65. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Integra Lifesciences Holdings stock overvalued right now?
Based on GuruFocus' analysis, Integra Lifesciences Holdings (STU:IL3) is currently considered Modestly Undervalued. The stock's GF Value™ is €20.79, compared to a current price of €16.40 — trading 21.1% below its estimated fair value. The current OCF Margin % is 2.50%, which is 80% below median its 10-year median of 12.65 and 57% below the Medical Devices & Instruments industry median of 5.82. Integra Lifesciences Holdings' overall GF Score™ is 74/100 with 11 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Margin % calculated?
OCF Margin % is calculated from a company's financial statements. For Integra Lifesciences Holdings (STU:IL3), the current OCF Margin % is 2.50% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Integra Lifesciences Holdings (STU:IL3) Overvalued in 2026?
Based on GuruFocus' analysis, Integra Lifesciences Holdings stock appears to be undervalued.
The current stock price of €16.40 is trading 21.1% below its estimated GF Value™ of €20.79.
GuruFocus considers Integra Lifesciences Holdings to be Modestly Undervalued.
Key valuation signals for STU:IL3:
OCF Margin %: 2.50% (80% below median its 10-year median of 12.65)
GF Value™: €20.79 vs. price of €16.40 (21.1% below fair value)
Industry Position: 57% below the Medical Devices & Instruments median (#438 of 817)
No single metric tells the full story. See the STU:IL3 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Integra Lifesciences Holdings Business Description
Integra Lifesciences Holdings Corp is a New Jersey-based medical equipment company focused on developing products for regenerative therapy, extremity orthopedics, and neurosurgical applications. The firm is organized into two primary segments: Codman specialty surgical and Tissue technologies. Codman Specialty Surgical generates maximum revenue from its segmental operations. Integra serves Europe, Asia Pacific, and the rest of the world whilst it derives key revenue from domestic sales. The company operates in United States, Europe, Asia Pacific, and Rest of the World.
74GF Score
Get the complete analysis for STU:IL3
OCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:IL3 has been successfully added to your 
